The UK start-up Pneumagen Ltd has been working on a novel way of blocking the entry of pathogens including influenza and coronaviruses into human cells, and expects to start clinical studies with its lead product, Neumifil, a multivalent protein, in 2021.
The technology under development by Pneumagen has its origins in research conducted more than 10 years ago at St Andrews...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?